inWhite tw_white-black
MoreMenu
CloseWhite
inWhite tw_white-black

News

Asgard Therapeutics to present positive in vivo efficacy data with AT-108 as monotherapy at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting 

Asgard Therapeutics Strengthens Scientific Advisory Board with Two Appointments

Asgard Therapeutics announces publication on direct reprogramming of cancer cells to force antigen presentation, in collaboration with Lund University

Eurostars-funded REPRINT consortium reaches milestones with evidence of complete tumor regression induced by dendritic cell reprogramming

Asgard Therapeutics highlighted at the Labiotech article “Investors Flock to Startups Reprogramming Cell Therapies”

Posted 25 November, 2021